GenFleet Therapeutics (2595.HK), a commercial-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, was listed on the main board of the Hong Kong Stock Exchange on Sept 19. The gross proceeds prior to the exercise of the over-allotment option reached USD 233 million, and will increase to USD 268 million after the exercise of the over-allotment option, making it the largest IPO fundraising under Chapter 18 rule on the Hong Kong Stock Exchange (HKEX) since 2022. Nine cornerstone investors were introduced into this IPO, including RTW Funds, OrbiMed, TruMed, UBS Asset Management (Singapore) Ltd., Vivo Funds, CUAM Entities, Fullgoal Entities, Tibet Longrising, Lake Bleu Entities, with cornerstone subscriptions totaling USD 100 million. CITIC Securities acted as the sole sponsor for this IPO.
"Over the past eight years, we've built a powerful pipeline that includes the first China-developed KRAS inhibitor. Anchored by a leading-edge RAS-targeted matrix, the pipeline tackles critical unmet needs globally in cancers such as pancreatic, lung, and colorectal cancer. Riding the waves of innovation, we've kept moving forward and delivered novel therapeutics and solid out-licensing milestones, for the benefit of patients and the value creation of shareholders." stated Qiang Lu, Ph.D., Chairman of GenFleet Therapeutics, on the listing ceremony.
GenFleet was the first biotech to enter the HKEX under Chapter 18A with a commercially launched product (fulzerasib) as well as established licensing revenue at the stage of IPO. Through proprietary R&D and collaborations with partners in China and abroad, the company has set up a highly differentiated pipeline of RAS-targeted matrix and diversified innovative treatments - with multiple assets leading their categories in clinical progress, in China or globally. In addition, the company has pioneered a series of first-in-class combination therapies based on dual-target synergistic mechanisms. By integrating clinical needs and insights, GenFleet is dedicated to expanding its portfolio into major therapeutic areas including pancreatic cancer, first-line NSCLC, and cachexia.
"The listing represents a significant milestone for the company and marks a new start as we advance into the future. The enhanced capital backing from the secondary market will accelerate the development of our core products and the progress in late-stage clinical trials. We are dedicated to building trusted partnerships with investors and fulfilling our mission to meet unmet clinical needs, consistently creating shared value for all patients and stakeholders.”stated by Jiong Lan, Ph.D., CEO of GenFleet.
Forward-looking Statements
Specific information in this press release may contain or constitute forward-looking words that are not historical facts. They can be identified by using forward-looking terminology, such as "predict", "believe", "plan", "predict", "expect", "will", "may", "should" and other words of similar meanings.Based on the management's current beliefs, plans, estimates and expectations of the company's operation and market trends subject to changes beyond control, the forward-looking terminology reflects GenFleet Therapeutics' beliefs, plans, estimates and expectations of future development. Actual outcome in the future may differ significantly from forward-looking words owing to market, policy, and R&D uncertainties, among others.Subject to the above-mentioned uncertainties, GenFleet Therapeutics makes no expressed or implied guarantee as to the accuracy, completeness or feasibility of this presentation, and you are cautioned not to solely rely on such forward-looking words.Neither the company nor any of its directors, officers, employees, shareholders, agents, related parties, consultants or representatives will be liable to you or any other person for consequences resulting from using this presentation. Investors are advised to exercise due diligence with reference to the company's official disclosures for decision-making.
